Clonal Architecture of EGFR Mutation Predicts the Efficacy of EGFR-Tyrosine Kinase Inhibitors in Advanced NSCLC: A Prospective Multicenter Study (NCT03059641).
Xinghao AiJiuwei CuiJiexia ZhangRongrong ChenWen LinCongying XieAnwen LiuJunping ZhangWeihua YangXiaohua HuXiaohua HuQiong ZhaoChuangzhou RaoYuan-Sheng ZangRuiling NingPansong LiLianpeng ChangXin YiShun LuPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Paired tissue and ctDNA could be analyzed for clonal architecture in advanced cancer. EGFR mutations do not always make up a dominant clone in advanced NSCLC, which was associated with the efficacy of EGFR-TKIs in NSCLC.